ATMP2030 releases annual ATMP report for 2024

ATMP2030 unveils the latest comprehensive sector report “Advanced Therapy Medicinal Products (ATMP) Annual Report of 2024” providing key insights into the rapidly evolving ATMP sector with focus on the Swedish market with Nordic and global outlooks. A webinar will be held the 25th of October presenting and discussion the report. The event will be in English and is free to attend online. Presentation of Swedish annual ATMP report | ATMP Sweden

SEE THE EVENT RECORDING!

Recording of 25th October 2024 report presentation This in-depth annual report has been created by the Vinnova funded innovation milieu “Sweden a world leader in development and implementation of advanced therapies by 2030”, (ATMP2030) in collaboration with Triathlon HealthTech. With a data driven approach, the report provides an overview of recent developments within the sector including detailed company landscape, research and publication data, ATMP in healthcare and clinicals trials as well as employment opportunity analysis. Interesting insights include;

• 25 SME ATMP developers in Sweden - 183% increase in employees since 2018 - 201 new employees
• Over 700 Nordic job postings in ATMP between 2020-2024, Denmark with 519, Sweden second at 156
• ATMP clinical trials double from 2021 to 2024 and counting - at least 48 currently active
• 77% increase in CAR T treatments from 2022-2024 and counting - 146 infusions given as standard of care
• Swedish SME developers receive over 16 million euros in EU funding
• Sweden is leading Europe in ATMP publications per capita and continues to increase
• 7 recommended ATMPs in Sweden - 4 CAR T and 3 gene therapy. 6 more under investigation by TLV/NT-Rådet
• 8 patients treated with Luxturna, 9 Zolgensma and 1 Libmeldy

“The latest annual report produced by ATMP2030, underscores the transformative developments of ATMPs since the baselining the project initiated in 2019. ATMPs have become more common in Swedish healthcare, with several inaugurated ATMP Centers and numerous advanced therapies recommended by NT-rådet. The development of new advanced therapies continues, recognized by the wide range of clinical studies and research performed by ATMP developers in Sweden and in other parts of the world. Advanced therapies hold great promise with their ability to cure diseases previously seen as incurable and will likely remain an important therapy area, with Sweden as a strong contributor in the Nordics” said Johan Hyllner, board member Centre for Advanced Medical Products. As the ATMP landscape continues to evolve, the report aims to equip area professionals with fact-based insights to get a detailed understanding of the current state and prepare for the future as more patients access advanced therapies. The report in its entirety can be found here, with other important reports initiated by Swedish National projects. The report will be presented during an online seminar, details to come. For more information, please contact Jennifer Rosendahl, project manager of ATMP2030.

About ATMP2030

This ’Vision Driven Innovation Milieu’ works to implement transformation of the systems required to make Sweden 'world leading in ATMP by 2030'. This inclusive platform works with a common vision to bring together relevant stakeholders to build Sweden's national capabilities and international competitiveness, drive accessibility of advanced therapies and increase knowledge and competence development needs. The project is part of the the Vinnova Vision Driven Health program.

About Triathlon HealthTech

Triathlon HealthTech is part of the Triathlon consulting firm with a specialized focus on enabling innovation and growth within the Life Science sector. We believe in working closely with our clients to truly understand their needs and create customized solutions that deliver results. We don't just advise; we work alongside our clients to actually make change happen.